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Background/aim: We aim to determine the effects of low-dose atorvastatin treatment together with crush fluid resuscitation on renal
functions and muscle enzyme levels in a rat model of crush syndrome.
Materials and methods: The study involved female Wistar Albino rats weighing 250–300 g that were housed with free access to food
and water. The crush model was obtained by compression. Rats were randomly divided into four groups: control (C) group, atorvastatin
+ crush fluid (ACF) group, crush fluid (CF) group, and hypertonic saline (%3) + mannitol + sodium bicarbonate (SM) group. Blood was
obtained at 24, 48, and 72 h, and serum creatinine kinase, myoglobin, urea, creatinine, and lactate dehydrogenase levels were studied.
Results: All parameters were statistically significantly higher in the control group than in the treatment groups at all hours. However,
there was no statistically significant difference among treatment groups regarding any of the parameters.
Conclusion: This is the first study determining the role of atorvastatin in the treatment of renal ischemia/reperfusion injury in a crush
syndrome and rhabdomyolysis model setting. Larger studies with different atorvastatin doses are required to define the role of this drug
in the treatment of renal ischemia/reperfusion injury during crush syndrome.
Key words: Crush syndrome, atorvastatin, rhabdomyolysis

1. Introduction
Ischemia/reperfusion injury (IRI) is the mainstay
of organ damage in crush syndrome that develops
following prolonged continuous pressure on the limbs
(1). Unfortunately, re-establishment of the blood supply
after a prolonged limb compression results in local
muscle cell necrosis and consequent rhabdomyolysis.
Moreover, the metabolites and cytokines leaked from
the myocytes of disintegrated muscle tissue may induce
systemic inflammatory response and multiple organ
dysfunctions (2). The reperfusion injury is associated
with the release of oxygen-free radicals and massive
accumulation of calcium in ischemic muscles. Recently,
oxidative stress, as determined using a free radical
elective evaluator, was reported to be markedly increased
after ischemia/reperfusion injury (3).
Prevention of reperfusion-induced injury of
ischemic muscles is extremely important because it
results in salvage of cells (4). Atorvastatin is a HMG-Co
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A enzyme inhibitor that is on the market primarily as
a lipid-decreasing agent. However, the antioxidant and
antiinflammatory properties of statins have been known
for years. A dose-dependent reduction and normalization
of oxidative stress marker levels in joint inflammation
has been reported after atorvastatin administration (5).
In a recent meta-analysis of 8 randomized trials, the use
of short-term statins was associated with a reduction
in the incidence of contrast-induced nephropathy, and
was recommended even in patients with low LDLcholesterol levels (6). On the other hand, myotoxicity
is one of the adverse effects of statins and may lead to
a large spectrum of muscle diseases, resulting from
myalgia or myopathy to rhabdomyolysis in a dosedependent manner (7).
In this study, we aimed to determine the effects of
low-dose atorvastatin treatment together with crush
fluid resuscitation on renal functions and muscle
enzyme levels in a rat model of crush syndrome.
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2. Materials and methods
2.1. Rats and crush model
Female Wistar Albino rats, weighing 250–300 g, were
housed in a room maintained at a temperature of 22 °C
and a relative humidity of 55%, with a 12-h light–dark
cycle and free access to food and water (ad libitum). The
study was approved by the Ankara Experimental Animal
Laboratory Ethics Committee and all animal experiments
were conducted according to guidelines for animal use.
To compress bilateral hind limbs, we prepared a pair of
rubber tourniquets that were 2.4 cm in width and 1 mm
in thickness. The tourniquets were applied by wrapping 5
turns around a metal cylinder (22-mm outer diameter, 20mm inner diameter, and 70 mm in length) under a 2-kg
weight load, and the end of the band was glued. The rat was
held ventral surface up, and its foot was dropped through
the metal cylinder. Hind limb compression was induced
by pushing the tourniquet high onto the rat’s thigh. After 5
h, compression was released by cutting and removing the
tourniquet (Figures 1a and 1b) (8).
2.2. Experimental design
The rats were randomly divided into four groups: control
(C) group, atorvastatin + crush fluid (ACF) group, crush
fluid (CF) group, and hypertonic saline (3%) + mannitol +
sodium bicarbonate (SM) group.
All experiments were conducted under general
anesthesia (80 mg/kg intraperitoneal ketamine
hydrochloride and 5 mg/kg xylazine). Compression was
performed in all groups. The control group did not receive
any treatment after compression. After the removal of
the tourniquets, the rats in the ACF group obtained
atorvastatin (ampule 100 mg, Sanofi Aventis, İstanbul,
Turkey) 0.2 mg/kg and concomitant crush fluid. The
CF group only obtained crush fluid, and the SM group
obtained hypertonic saline (3%) + mannitol + sodium
bicarbonate together. The tail vein was catheterized for
the iv fluid infusions. The infusion rate of the fluids was
1 mL/100 g body weight/hour. The fluid amount was
calculated and administered at 2, 4, and 6 h by iv bolus.
Blood was obtained at 24, 48, and 72 h, and serum
creatinine kinase (CK), myoglobin, urea, creatinine and
lactate dehydrogenase (LDH) levels were studied. At 24
and 48 h, a 1.5–2 cc blood sample was obtained from rat tail
veins. At 72 h, the blood was obtained in an intracardiac
way under general anesthesia, and the rats were sacrificed
this way.
2.3. Statistical analysis
Data are shown as mean ± standard deviation. Statistical
analysis of data was performed using SPSS 21.0. Two-way
analysis of variance (ANOVA) was used for comparison
of all groups with Tukey posthoc tests. A 95% confidence
interval was considered statistically significant (P < 0.05).

Figure 1a and 1b. Crush syndrome model.

3. Results
The survival rates of the rats remained at 100% throughout
the experiment. All rats completed the study.
The mean results of the groups at 24, 48, and 72 h are
summarized in Tables 1–3, respectively. All parameters
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Table 1. Results at 24 h.
Control

ACF

CF

SM

P

BUN (mg/dL)

39.75 ± 5.59

17.50 ± 9.53

20.75 ± 12.17

19.87 ± 8.50

0.03

Creatinine (mg/dL)

0.62 ± 0.17

0.37 ± 0.14

0.56 ± 0.32

0.37 ± 0.39

0.007

CK (IU/L)

780.42 ± 126.52

160.87 ± 185.29

197.37 ± 95.39

425.12 ± 330.68

0.008

LDH (IU/L)

1483.14 ± 421.90

429.37 ± 176.56

496.75 ± 180.93

815.75 ± 393.55

0.04

BUN: blood urea nitrogen, CK: creatinine kinase, LDH: lactate dehydrogenase.
Table 2. Results at 48 h.
Control

ACF

CF

SM

P

BUN (mg/dL)

59.46 ± 11.61

15.12 ± 4.81

17.37 ± 4.49

18.50 ± 5.41

0.001

Creatinine (mg/dL)

1. 11 ± 0.42

0.23 ± 0.14

0.27 ± 0.11

0.24 ± 0.12

0.01

CK (IU/L)

1086.25 ± 532.04

152.00 ± 138.72

189.50 ± 128.95

228.62 ± 149.82

0.04

LDH (IU/L)

1014.75 ± 528.25

325.87 ± 162.80

374.25 ± 103.97

422.25 ± 164.26

0.005

BUN: Blood urea nitrogen, CK: creatinine kinase, LDH: lactate dehydrogenase.
Table 3. Results at 72 h.
Control

ACF

CF

SM

P

BUN (mg/dL)

50.98 ± 7.02

17.66 ± 1.10

20.68 ± 1.34

19.66 ± 2.53

0.03

Creatinine (mg/dL)

0. 79 ± 0.34

0.25 ± 0.32

0.27 ± 0.12

0.27 ± 0.07

0.02

CK (IU/L)

562.50 ± 182.05

270.00 ± 171.49

310.00 ± 108.37

441.25 ± 192.44

0.01

LDH (IU/L)

743.00 ± 154. 92

190.37 ± 92.99

245.85 ± 106.48

191.37 ± 94.64

0.01

BUN: blood urea nitrogen, CK: creatinine kinase, LDH: lactate dehydrogenase.

were statistically significantly higher in the control group
than in the treatment groups at all hours. At 24 h, the
BUN value of the control group was significantly higher
than those of the ACF, CF, and SM groups (P = 0.028).
Creatinine values were statistically significantly higher in
the control group than in the ACF and SM groups (P =
0.030 and P = 0.032, respectively). The CK value of the CF
group was significantly lower than the value determined in
the control group (P = 0.016). At 48 h, the BUN values of
the control group were significantly higher than the BUN
values in the ACF, CF, and SM groups (P = 0.0001, P =
0.0001, and P = 0.0001, respectively). The creatinine values
of the control group were significantly higher than those of
the ACF, CF, and SM groups (P = 0.007, P = 0.012, and P =
0.006, respectively). CK level detected in the SM group was
significantly lower than the value determined in the control
group (P = 0.020). The LDH level in the control group was
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significantly higher than the levels in the ACF, CF, and SM
groups (P = 0.002, P = 0.003, and P = 0.004, respectively).
At 72 h, BUN values of the control group were significantly
higher than the values in the ACF, CF, and SM groups
(P = 0.012, P = 0.016, and P = 0.018, respectively). The
creatinine values of the control group were significantly
higher than those of the ACF, CF, and SM groups (P =
0.001, P = 0.001, and P = 0.001, respectively). CK levels
in the SM group were significantly lower than the value
determined in the control group (P = 0.070). The LDH
level in the control group was significantly higher than
the levels in the ACF, CF, and SM groups (P = 0.016, P =
0.021, and P = 0.030, respectively). However, there was no
significant difference between treatment groups regarding
any of the parameters.
The laboratory measured myoglobin levels as normal
or higher than normal. In this respect, at 24 h only one
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rat in the control group had higher myoglobin levels than
normal; at 48 h, one rat in the C group and one rat of the
CF group had higher myoglobin levels than normal; at
72 h, 4 rats of the C group, 4 rats of the CF group, 2 rats
of the ACF group, and 2 rats of the SM group had higher
myoglobin levels than normal. There was no significant
difference among groups regarding myoglobin levels at
any time.
4. Discussion
In this study, we evaluated the effects of atorvastatin
treatment together with crush fluid in a rat crush model.
We determined that the addition of atorvastatin to the
crush fluid did not result in any significant difference in
renal functions or muscle enzyme levels when compared
to other treatment (only crush fluid or hypertonic saline
treatments) groups. Although the means of all parameters
were lower in the atorvastatin group than in the other
groups at all hours, the difference was not significant
between treatment groups.
Acute limb ischemia results in a sudden onset decline
in the perfusion of the limbs that threatens both the limb
functions and patients’ lives (9).
Muscle cell ischemia and massive cell death result
in the release of myoglobin, potassium, and lactic acid.
Acute reperfusion of muscle compartments causes
sudden intravascular spreading of these toxic metabolites,
resulting in acute rhabdomyolysis and renal failure (10).
Data about the renal therapeutic effects of statins
in IRI are limited. Sabbatini et al. reported that lowdose treatment with atorvastatin enhances nitric oxide
availability, improving renal dynamics and conferring a
histologic protection at tubular level after ischemia in an
experimental study (11).
Tododrovic et al. investigated the effects of acute
pretreatment with a single dose of simvastatin (1 mg/
kg, iv; 30 min before ischemia) on renal dysfunction
caused by IRI in the rats. They reported that simvastatin
significantly improved both parameters of glomerular
and tubular dysfunction, and especially improved the
histological score compared to rats treated with saline or
10% dimethylsulfoxide only (12).
Haylor et al. reported that 10 mg/kg atorvastatin,
administered after clamping the renal hilus but prior
to kidney reperfusion, significantly reduced tubular
apoptosis, necrosis, and interstitial apoptosis, as well as
caspase-3 activity, but did not change serum creatinine
and cholesterol levels (13).
Tucci Jr et al. investigated the effects of lovastatin (15 mg/
kg per day) on renal ischemia, followed by reperfusion on 31
rats, and reported significantly lower mortality rates as well
as serum urea and creatinine levels in the lovastatin group
compared to the control cases without any treatment (14).

Very recently, Wu et al. tested the hypothesis that
postischemic acute renal failure could be ameliorated
with atorvastatin in 24 rats, and reported that atorvastatin
treatment reduced the elevation of serum creatinine level
by 18%. Moreover, concentrations of advanced oxidation
protein products and malondialdehyde were reduced in
the atorvastatin group (15). Interestingly, in that study,
atorvastatin was injected 30 min before reperfusion, not
after reperfusion, and at a dose of 10 mg/kg, which was
much higher than the doses used in our study.
In recent years, several different antioxidant treatments
have been suggested to diminish IRI in crush syndrome.
Murata et al. evaluated the role of nitrite as a therapeutic
agent for crush syndrome. They reported that nitrite
administration restored nitric oxide bioavailability by
enhancing nitrite levels of the muscle, resulting in a
reduction of rhabdomyolysis markers such as potassium,
lactate dehydrogenase, and creatine phosphokinase in rats
(16).
Similarly, Murata et al. studied a rat model to define
the therapeutic role of dexamethasone in the laboratory
findings, clinical course, and outcome of crush syndrome.
They reported that a single injection of high-dose
dexamethasone immediately before reperfusion activated
endothelial nitric oxide synthase (eNOS) and exhibited
antiinflammatory effects by modulating proinflammatory
and antiinflammatory mediators, resulting in a complete
recovery of the rats from lethal crush syndrome (17).
Recently, Garbaisz et al. studied a mitochondria-specific
drug, NIM-811 (N-methyl-4-isoleucine-cyclosporin),
which can prevent IRI in a rat model. They reported that
muscle mitochondrial viability proved to be significantly
higher and renal function parameters significantly better
in the treatment group (18).
To the best of our knowledge, this study is the first
to determine the role of atorvastatin in the treatment of
renal IRI in a crush syndrome and rhabdomyolysis model
setting. One of the most common side effects of statins is
the statin-associated myopathy that is reported in about
10%–15% of statin users in observational studies (19,20),
and this adverse effect was determined to have a doseresponse relationship (21). For that reason, a low dose of
statin was administered to the rats in this study.
There are certain limitations to this study. Firstly, the
number of rats used in the study was not high in order to
protect rats from redundant injury. Secondly, the treatment
period was brief. The rats were only treated from their
tail veins for the first 6 h, which may not be sufficient to
determine their direct effects. Lastly, we did not measure
the oxidant–antioxidant status of the rats, nor did we
evaluate their kidneys histopathologically, which may be
important in showing the effects of treatment directly.
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In conclusion, we investigated the potential therapeutic
role of low-dose atorvastatin treatment, as an antioxidant
and antiinflammatory agent, on renal functions of rats
with crush syndrome and rhabdomyolysis. Although
there was an improvement in the renal functions of rats

following atorvastatin administration, the difference
was not significant when compared to other treatment
groups. Larger studies with different atorvastatin doses are
required to define the role of this drug in the treatment of
renal IRI during crush syndrome.
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